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Background: In August 2010, the Federal Joint Committee (G-BA) decided that negative pressure wound therapy
(NPWT) would not be reimbursable in German ambulatory care. This decision was based on reports from the
Institute for Quality and Efficiency in Health Care (IQWiG), which concluded that there is no convincing evidence in
favor of NPWT. The aim of this diabetic foot study (DiaFu study) is to evaluate whether the clinical, safety and
economic results of NPWT are superior to the results of standard wound treatment.
Methods/Design: The DiaFu study is designed as a national, multicenter, randomized controlled clinical superiority
trial with a special focus on outpatient care in Germany. Competent patients in inpatient and outpatient care
suffering from a chronic diabetic foot wound for a minimum of four weeks may be included in the study. The trial
evaluates the treatment outcome of the application of a technical medical device which is based on the principle
of NPWT (intervention group) in comparison to standard moist wound therapy (control group). All treatment
systems used in the intervention group bear the symbol of free trade capacity in the European Union (CE mark)
and will be operated within normal conditions of clinical routine and according to manufacturer’s instructions.
Primary endpoints are the time to complete wound healing and the rate of wound healing achieved in each group
within the maximum study treatment time of 16 weeks. Primary endpoints will be confirmed by blinded
assessment of wound photographs.
Discussion: The DiaFu study will provide solid evidence regarding the efficacy and effectiveness of NPWT until 31
December 2014, the date when G-BA plans to decide on future reimbursement of NPWT in both ambulatory and
in-hospital care. The study is designed to comply with all quality requirements of G-BA and IQWiG and will contribute
to evidence-based wound care in Germany. The study has been initiated by the statutory health insurance companies
in Germany and is co-funded by two manufacturers of NPWT systems.
Trial registration: Clinical Trials.gov registration number: NCT01480362 (date of registration: 23 November 2011).
German Clinical Trials Register number: DRKS00003347 (date of registration: 22 November 2011).
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Diabetes and diabetic foot wounds
Diabetes mellitus (DM) is a prevalent global chronic disease
and describes a metabolic disorder. It is characterized by
chronic hyperglycemia and disturbances in carbohydrate,
fat and protein metabolism. These disturbances result from
an inability of the pancreas to produce enough insulin, the
body’s inability for an effective use of the produced hor-
mone, or both.
The World Health Organization (WHO) estimates that
more than 180 million people worldwide suffer from dia-
betes [1]. Even higher numbers have been predicted by the
International Diabetes Federation (IDF), who reported in
2003 that 194 million adults were diagnosed with diabetes
[2]. Both organizations estimate that in 2030 the number
of those diagnosed will have almost doubled, mainly due
to demographic changes [3]. Diabetes management in-
volves a variety of costs and imposes enormous resource
burdens, both on the individual and on healthcare sys-
tems. Diabetes and its sequelae cause significant economic
consequences on individuals, families, health systems and
countries. The WHO has estimated that 2.5 to 15% of an-
nual national healthcare budgets are spent on diabetes-
related illness alone [1].
The Diabetic foot wound is a common and frequent
secondary syndrome that can lead to amputation. Due to
arterial abnormalities and diabetic neuropathy, as well as a
tendency to delay wound healing, infection or gangrene of
the foot may develop. Acute and chronic wounds with
healing impairment are a common problem of healthcare
[4]. Complications associated with non-healing wounds
range from inconvenient to life threatening and can be
more common and serious than those related to the under-
lying disease. The occurrence of impaired wound-healing
represents a multi-disciplinary treatment and cost-intensive
clinical problem whether it is caused by infectious or non-
infectious reasons.Modern wound treatment and negative pressure wound
therapy
Modern wound treatment concepts include different types
of moist dressings and topical agents, although only a few
of these treatments have been convincingly shown to give
higher wound closure rates compared with traditional wet
gauze dressings [5,6].
Negative pressure wound therapy (NPWT) was devel-
oped at the Wake Forest University (Winston-Salem,
North Carolina) in the early 1990s [7,8]. NPWT consists
of an open-cell foam dressing covered with an adhesive
drape. The dressing is connected to a vacuum pump that
creates and maintains a sub-atmospheric pressure (inter-
mittent or continuous). Positive effects of NPWT on
wound healing have been demonstrated in basic studies[8,9], and many case reports and case series document a
broad use of NPWT in various clinical settings.
Recent history of NPWT - clear evidence is still missing
In 2004 the German Federal Joint Committee (Gemeinsa-
mer Bundesausschuss (G-BA)) commissioned an analysis of
the available studies regarding NPWT to the Institute for
Quality and Efficiency in Healthcare (Institut für Qualität
und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)) to
support decision-making on the reimbursement of NPWT
by the German statutory health insurance funds. The G-BA
is the legislative institution of the German healthcare self-
administration system. The IQWiG is an independent non-
profit and non-government scientific institute that receives
commissions from the Federal Joint Committee and the
German Ministry of Health. The performed analysis aimed
to evaluate the clinical benefit of NPWT in comparison
with conventional forms of wound care, and to compare
the benefit of various forms of NPWT for acute and
chronic wounds with regard to patient-relevant outcomes
on the basis of the published literature. The systematic
examination of the clinical effectiveness and safety of
NPWT compared with conventional wound therapy con-
cluded that although there is some indication that NPWT
may improve wound healing, the body of evidence avail-
able is insufficient to clearly prove an additional clinical
benefit of NPWT. In addition, the large number of prema-
turely terminated and unpublished trials has been a reason
for concern [10-12]. A 2007 Cochrane review concluded
that trials comparing topical negative pressure (TNP) with
alternative treatments for chronic wounds have methodo-
logical flaws and data do demonstrate a beneficial effect of
TNP on wound healing. However, further better quality
research is needed [13]. In 2011 Peinemann and Sauerland
updated the systematic literature review [14] and con-
cluded that although there may be a positive effect of
NPWT, a clear evidence that wounds heal any better or
worse with NPWT than with conventional treatment is
still missing and better RCTs are still needed to evaluate
NPWT. A Cochrane intervention review performed in
2013 concluded that there is some evidence to suggest that
NPWT is more effective in healing post-operative foot
wounds and ulcers of the foot in people with DM com-
pared with moist wound dressings. However, these findings
are uncertain due to the possible risk of bias in the original
studies [15]. Therefore it can be concluded that current
RCT evidence is limited and further trials are required to
reduce uncertainty around decision-making regarding the
use of NPWT to treat foot wounds in people with DM.
Aim of the DiaFu study
This RCT is designed to prove that NPWT therapy leads
more frequent and earlier to complete healing of dia-
betic foot wounds as compared to conventional moist
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NPWT therapy is also safe and effective when provided
in an ambulatory care setting and to prove its overall
cost-effectiveness. This trial is designed to comply with
all quality requirements (randomized trial, low potential
for bias; see Discussion section) of IQWiG and G-BA, as
well as other European authorities.Methods/Design
The DiaFu study is designed as a national, multicenter,
randomized controlled clinical superiority trial across
Germany, with blinded photographic analysis of the pri-
mary endpoint. Participants are randomly allocated in a
1:1 ratio to each treatment group. Allocation to treat-
ment groups is performed using a centralized web-based
tool. To ensure good balance of participant characteris-
tics in each group a stratified randomization is per-
formed. Participants are stratified by study centre and by
Wagner-Armstrong stage within each centre (<Wagner-
Armstrong stage 2C and ≥Wagner-Armstrong stage 2C;
Figure 1). Due to the physical differences between the
treatment regimens it is not possible to blind either par-
ticipant or physician to the treatment arm. To address



























Figure 1 Stratification of DiaFu study participants according to Wag
stratified by study center and by Wagner-Armstrong stage within each ce
Armstrong stage 2C). The table shows the modified Wagner-Armstrong c
2 is marked red.assessed via blinded assessment of wound photographs
by independent observers.Phase and classification of the trial
The study is classified as an examination of the clinical
application of CE-marked medical devices with risk cat-
egory 2b (increased methodical risk) according to risk
classification rules based on the annex IX of the Euro-
pean Union (EU) Directive 93/42 / European Economic
Community (EEC). According to the German Medical
Device Act (MPG) the trial is classified as an exemption
to clinical investigation according to paragraph 23b
MPG. This is due to the fact that the investigational de-
vices are CE-marked, will only be operated within
intended use and there will be no additional invasive or
otherwise straining examinations. Examination results
will only be documented if collected within clinical rou-
tine. Ethical approval of the Lead Ethical Committee
(LEC, German: Federführende Ethikkommission) ‘Ethical
Committee of the University of Witten/Herdecke’ has
been fully granted without any conditions. As the trial
will be performed in accordance with paragraph 23b
MPG, further participating centers in Germany will only
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ing centers in Germany is not applicable.
Setting
This multicentre study will be conducted in hospital de-
partments and/or outpatient facilities with a special quali-
fication for diabetic foot care (Figure 2). Study therapy will
be started in-hospital or in ambulatory care and should be
continued in ambulatory care whenever possible. The
maximum study treatment time is set as 16 weeks after
randomization and initiation of therapy. Randomized
wound therapy must be started no later than six hours
after the last wound preparation which can either be a
wound cleansing, debridement or an amputation.
If a patient requires further local wound treatment after
the end of the maximum study treatment time either
standard wound treatment or NPWT may be performed
as estimated by the treating physician to provide optimal
wound care.
Participants
All consecutive eligible adult patients (age >18 years) with
a diabetic foot lesion corresponding to Wagner 2 to 4 that
has continuously existed for a minimum of four weeks,
who meet all inclusion criteria and no exclusion criteria,
may be included in the trial. Chronic diabetic foot wounds
after adequate wound pretreatment (debridement and/or
wound cleansing) as well as amputation wounds resulting
from a planned amputation underneath the upper ankle
joint (lat.: Articulatio talocruralis) may be considered for
inclusion. Therefore the main part of the wound is not
allowed to be located above the upper ankle joint. Before
randomization, inclusion in the trial and any trial-related
procedure the participant must have provided written in-
formed consent. Figure 3 provides a full overview of the in-
clusion and exclusion criteria. Reasons for non-enrolment
or non-eligibility will be documented for all patients who
fulfil the inclusion criteria but who are not included in the
trial.
Any inability of the patient to respond to requests, to
adequately assess risk or to comply with the require-
ments of the course of study, both in the inpatient and
outpatient therapy episode, must be considered as non-
compliance. If, in the estimation of the clinical investiga-
tor, a patient is non-compliant at the time of inclusion
or is expected to be non-compliant during the course of
the trial, this patient may not be included. Contraindica-
tions for the application of a NPWT device that result
from a recommendation or a warning from the Food
and Drug Administration (FDA) or from the manufac-
turers’ guidelines for product use are exclusion criteria
for this trial. Patients with presence of necrotic tissue with
slough and scab that cannot be debrided are not allowed
to be included in the trial. Prior to randomization andstart of study treatment, if necessary, a sufficient debride-
ment or a radical removal of necrotic tissue in terms of an
amputation should be carried out. If parts of the necrotic
tissue cannot be removed by debridement or amputation,
the patient should not be included in the study. Special at-
tention has to be paid to exposed blood vessels within the
wound or the direct wound surrounding that cannot be
protected or that carry an increased risk of bleeding with
relevant circulatory effects. If a sufficient covering is not
possible, the patient should not be included in the study
Patients may not be included if they are receiving anticoa-
gulation therapy or are suffering from a higher grade im-
paired clotting function and have a heightened risk for
bleeding with relevant circulatory effects if those patients
are in outpatient care during the time of inclusion. If treat-
ment systems which are based on the principle of NPWT
have been used at the study-related foot lesion within a
period of at least six weeks prior to the start of the study
these patients may not be included in the trial. This is due
to the objective of the study to demonstrate and evaluate
a clear therapeutic effect of each treatment arm.Intervention and control
In the intervention group medical devices using the
principle of NPWT will be applied on the study wound
[7,8]. This therapeutic technique uses a vacuum dressing
to promote healing. The therapy involves the controlled
application of sub-atmospheric pressure to the local wound
environment, using a sealed wound dressing connected to
a vacuum pump. NPWT promotes wound healing through
optimization of blood flow, decreasing local tissue edema
and removing excessive fluid from the wound bed. These
physiologic changes facilitate the removal of bacteria from
the wound. Additionally, the cyclical application of sub-
atmospheric pressure alters the cytoskeleton of the cells in
the wound bed through microstrain, triggering a cascade
of intracellular signals that increase the rate of cell division
and subsequent formation of granulation tissue. Moreover,
this system has been shown to also cause macrostrain,
bringing the edges of the wound closer and also stimulat-
ing wound bed granulation. NPWT as interim therapy
should be discontinued once the condition of a wound is
suitable for closing, either spontaneously or surgically.
Table 1 gives an overview of the NPWT devices used
within the trial. Medical devices used within the trial are
all CE certified products. All NPWT devices and dressings
to be utilized in this study bear the CE mark and will be
operated within normal conditions of use and according
to clinical and manufacturers guidelines. Dressing changes
are recommended to be performed according to manufac-
turer’s instructions with frequency adjusted by the clin-
ician as appropriate. Contraindications and precautions
will be noted.
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Figure 2 DiaFu study sites. Recruitment of study patients is performed in hospitals and outpatient facilities across Germany with a specific
qualification for the treatment of chronic diabetic foot wounds. The table lists all study sites ready for patient recruitment as of 25 October 2013.
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Table 1 Used medical products within the trial
KCI Smith & nephew
NPWT devices
V.A.C. Freedom® RenasysTM GO




V.A.C.® Granufoam® (black) Foam dressing (RENASYSTM –F/P)
V.A.C.® Granufoam® silver® Gauze dressing (RENASYSTM –G)
V.A.C.® Whitefoam®
The table shows the NPWT devices of Kinetic Concepts Incorporated (KCI) and
Smith & nephew used within the trial.
Inclusion criteria: Exclusion criteria:
 Presence of a diabec foot wound corresponding to 
Wagner 2 - 4 
 Connuous existence of the diabec foot lesion for a 
minimum of 4 weeks
 Parcipant has given wrien informed consent
Age <18 years
Pregnancy
Present or expected non-compliance with the requirements of the 
study esmated by invesgator at me point of inclusion 
Indicaon for amputaon above the ankle level of the same 
extremity
Necroc ssue with eschar present that cannot be debrided
Untreated osteis or osteomyelis
Unexplored ﬁstula
Malignancy of the wound
Exposed nerves, vessels or anastomoc areas
Ambulant negave pressure wound therapy of paents with
ancoagulaon therapy or higher grade impaired clong funcon 
and a heightened risk for bleeding with relevant circulatory eﬀects 
Allergy to any disposal component of each treatment arm
Severe anemia which is not caused by an infecon
Simultaneous parcipaon in other intervenonal trials / previous 
parcipaon in this trial
Use of negave pressure wound therapy within 6 weeks prior to 
randomizaon 
Figure 3 Inclusion and exclusion criteria of the DiaFu study. The table shows the required diagnosis and the inclusion and exclusion criteria
for DiaFu participants.
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wound therapy according to local clinical standards and
guidelines [6]. Healthcare providers are obligated to pro-
vide patients with best practice and standard of care. In
the control arm it is permitted to apply every local wound
treatment standard used in the respective study site that
does not have an experimental status or is based on the
principle of NPWT.
To ensure the quality of local wound treatment during
the course of the study, the study sites are trained for both
the intervention arm and the control arm. The manufac-
turers are responsible for the training with the NPWT
systems and consumables (dressing materials). The
German Society for Wound Healing and Wound Treat-
ment (German: Deutsche Gesellschaft für Wundheilung
und Wundbehandlung e.V.) provides parts of their cur-
riculum and performs the training for the control arm.
Primary and secondary endpoints
Time until complete (100% epithelization) wound closure
and the number of wound closures in each treatment
group achieved in the maximum study treatment time of16 weeks (112 days) are the primary endpoints of the
DiaFu study. Complete wound closure is defined by 100%
epithelialization of the wound (no granulation tissue vis-
ible), no drainage, no sewing material and no need for
wound dressing or adjuvants. The assessment of complete
wound closure is primarily based on the central blinded re-
view of photographs performed by independent analyzers.
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or by secondary intention. However, surgical intervention
(for example wound suture, skin grafting or flap transplant-
ation) is allowed only if the wound bed is prepared ad-
equately. Sustainment of complete wound closure has to
be proven by a satisfactory follow-up examination of the
area 14 days after the intervention (wound closure verifica-
tion visit). If the wound cannot be closed before the end of
the maximum treatment time of 16 weeks, a study visit to
assess the wound status and for evaluation of the second-
ary endpoints is performed.
Secondary clinical endpoints are the time until complete
wound closure within the study time of six months, the
number of wound closures per treatment group achieved
within six months, the time until optimal preparation of
the wound bed for further treatment (a minimum of 95%
granulation), recurrences, amputations with incidence and
extent, the wound size over time (area of wound opening,
maximal length and width (cm2)) and the composition of
wound tissue (percentage of epithelial layer, granulation
tissue and fibrin).
The incidence of serious adverse events (SAEs) includ-
ing mortality of any cause within six months from the
time of initiation of therapy, incidence of device-related
adverse events (ADEs) and incidence of wound-related ad-
verse events (AEs) occurring within the study treatment
time of 16 weeks or until wound closure confirmation are
considered to be safety endpoints of this trial.
Furthermore, patient reported outcomes (PRO) will be
evaluated. Quality of life (QoL) is measured using the
questionnaire EQ5D. The questionnaire will be completed
by the participant at inclusion, end of the maximum treat-
ment time or end of the therapy and at the six-month
follow-up visit . Furthermore, during study visits partici-
pants will be asked to provide their assessments of pain
with a numerical rating scale (0 to 10). Participants will be
asked to provide an estimate of their wound-associated
pain of the last 24 hours at each trial visit.
Health economic evaluation and analysis
In addition to the evaluation of clinical treatment effective-
ness, a prospective assessment of health economic issues
with a focus on the direct medical costs of wound treat-
ment will be performed. This includes assessment of the
parameters relevant for inpatient and outpatient resource
use. A cost-effectiveness analysis using PRO and the num-
ber of wound closures as effectiveness measures will be per-
formed. The economic evaluation is performed from the
perspective of the German social insurance over the time
horizon of the study period. To estimate costs the resource
use is measured in natural units (for example duration of
dressing changes in minutes). The average resource use per
patient is calculated and priced with opportunity cost ap-
proximated over German market prices or schedule prices(for example wage agreements for staff costs). A sensitivity-
analysis is performed by replacing the mean costs and ef-
fects with the upper and lower bound of the respective 95%
confidence interval. Costs and effectiveness results are syn-
thesized in an incremental cost-effectiveness ratio.
Statistical analysis
The analysis of the primary and secondary endpoints
will be performed according to the intention-to-treat
principle (ITT). There will be no interim analysis. The
ITT analysis population will include all randomized par-
ticipants who have a valid baseline and at least one valid
post baseline wound assessment (examination). For the
ITT analysis population, participants will be assigned to
the treatment group based on the randomization sche-
dule, regardless of the treatment actually received. As a
secondary approach a per protocol (PP) analysis will be
performed excluding patients with any serious protocol
deviations and changes of wound treatment. The rates of
wound closure will be compared using Fisher’s exact test
and time to complete closure will be compared using
the Log-rank test. Safety data will be presented on an ‘as
treated’ basis where patients will be grouped according
to the exact wound treatment performed. Safety and sec-
ondary endpoints will be analyzed using conventional
univariate testing. For the analysis of the primary efficacy
endpoint missing values will be incorporated as censored
values.
Power calculation
The superiority hypothesis is tested in parallel with two
different outcomes for the rate of wound closure and the
time to wound closure in a fixed maximum treatment
period of 16 weeks. The method of Bonferroni-Holm
will be used for the adjustment of the α-error for parallel
confirmatory testing of both primary endpoints. This
means that after testing for both endpoints the smaller P
value has to be <0.025 while the other has to be <0.05
for statistical significance. The sample size calculation is
based primarily on the difference between wound clos-
ure rates in both treatment arms. The expected differ-
ence of the wound closure rates is based on information
extracted from published previous studies. Armstrong
and Lavery [16] described a rate of complete wound
closure within 56% of patients with NPWT and within
39% of patients in the corresponding control group.
Blume [17] showed a rate of complete wound closure
within 43% of patients treated with NPWT and 29% of
patients in the control group. For the present study suc-
cess rates for achieving of the primary endpoint of 45%
for NPWT and 30% in the control group are assumed,
resulting in an absolute difference of at least 15% in the
rate of complete wound closure results. Based on a type
one error of α = 0.05 and a type two error of β = 0.2
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162 patients per group (324 in total) is needed to prove
the primary endpoint (wound closure rate).Discussion
Trial preparation and organization
Within a European tender the study was initiated by
the statutory health insurance in Germany. A consor-
tium of 19 statutory health insurance funds including the
Federal Association of Local Health Insurance Funds (AOK-
Bundesverband), the Association of Substitute Health
Funds (vdek-Verband der Ersatzkassen e.V.), and the
Sickness Fund for Miners and Seamen (Knappschaft)
including the Maritime Health Insurance Fund (See-
Krankenkasse). These statutory health funds are the cen-
tral contact for the study project and all associated health
insurance funds provide integrated care contracts for am-
bulant NPWT of study patients. The Institute for Research
in Operative Medicine (German: Institut für Forschung
in der Operativen Medizin (IFOM) of the University of
Witten/Herdecke is an independent scientific institute
that is responsible for the scientific conception, analysis
and reporting of the study. Furthermore, IFOM moni-
tors the compliance with regulatory and quality require-
ments. The University of Witten/Herdecke has taken over
the sponsorship of the trial. A management company,
Gesundheitsforen Leipzig (GFL), is responsible for the lo-
gistics, the financial aspects and the study site selection, as
well as patient recruitment for the study. The study
database is provided and hosted by the GFL. The trial is
funded by the participating statutory health insurance com-
panies and the manufacturers Kinetic Concepts Incorpo-
rated (KCI) and Smith & Nephew (S&N). Both companies
provide the NPWT systems in the assigned regions of
Germany as well as all necessary information about the
used medical devices and associated consumable supplies.
Recruitment of study patients is performed in hospitals
and outpatient facilities with a specific qualification for
the treatment of chronic diabetic foot wounds all over
Germany. A webpage provides more information about
the overall study project. The website can be found using
the uniform resource locator http://www.wound-care.de.Ensuring outpatient care of study participants with NPWT
In Germany outpatient care with NPWT is not generally
reimbursed. To ensure the optimal patient-centered care
and to avoid any bias, the participating health insurance
companies are providing integrated care contracts for
NPWT in the ambulant treatment sector. Moreover, in-
tegrated care contracts are provided for the ambulant
NPWT of up to 7000 patients with acute and chronic
wounds in Germany.Healing characteristics of chronic wounds and
justification for the testing of two primary endpoints
Chronic diabetic foot wounds were chosen as the target
study population because they are considered to be a fair
representation of chronic wound types and also are fre-
quently associated with the types of comorbidities observed
with other types of open wounds. In chronic wounds the
balance of individual physiological processes of wound
healing is permanently disrupted and wound healing is
extremely difficult or impossible. Regarding the healing
time, stagnation within a non-healing state is observed.
The treatment of chronic wounds is often characterized
by prolonged or permanently insufficient applied thera-
peutic methods. The resumption of the physiological heal-
ing process in chronic wounds requires a longer start-up
process than in the acute wound, where the physiological
processes are in balance. The treatment of chronic wounds
such as diabetic foot wounds is an interdisciplinary chal-
lenge. In addition to the burden on the patient, the associ-
ated health-economic costs can be enormous. According to
Kaplan-Meier curves in the study of Blume [17] complete
wound closure using NPWT was achieved after an average
of 96 days, whereas the time for wound closure using
standard therapy was not determinable. Thus, in chronic
wounds the rate of achieved wound closures within a pre-
determined treatment time is of specific interest. This re-
sults in the definition of the primary endpoint as the
number of wound closures within the maximum study
treatment period of 16 weeks. In addition, a precise evalu-
ation of the time required to reach a complete wound clos-
ure comparing the two arms of the study is of primary
interest and of high economic importance.
Definition of chronic wounds
The available literature on the definition of a chronic
wound (for example expert standards and guidelines) shows
a very heterogeneous picture [18] and ranges from four to
eight weeks or more for minimum existence of the lesion.
It was decided that patients who suffer for four weeks
or longer from the continuous existence of a diabetes-
associated foot lesion are suitable for participation in
the present study.
Wound closure
The FDA 2006 Guidance for Industry [19] defines
complete wound closure as ‘skin closure without drain-
age or dressing requirements’. Wound closure can be
achieved by delayed primary intention (secondary suture,
skin flap or skin graft) or secondary intention according
to requirements of the participant and wound in the es-
timation of the attending physician. Optimal care for the
participant has to be ensured. Independent from type of
closure, criteria for wound closure have to be reached
within a maximum time frame of 112 days and wound
Table 2 Potential bias
Criteria for potential bias Explanation
RCT The performance of a randomized controlled trial is required.
Suitable allocation to groups A precise description of the randomization sequence generating procedure is required (such as computer-generated lists).
Allocation to groups suitably
concealed




Information on who (patient and/or researcher) assessed which endpoint under blinding conditions (without
knowing the group to which the patient had been allocated) is required.
Reasons given for any data loss The requirement is either no data loss or, if data loss is reported, identification of all patients whose data could not
be fully evaluated after randomization and the reasons for this (for example patients who dropped out before the
beginning of treatment or during follow-up).
Adequate ITT analysis Evaluation using the number of randomized patients as the size of the population is required
Seidel et al. Trials 2014, 15:334 Page 9 of 10
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secutive days. Within each treatment arm surgical wound
closure may only be performed if an adequate preparation
of the wound bed (minimum 95% granulation tissue) has
been achieved.
Avoiding potential bias
Within the reports of the IQWiG and the updated sys-
tematic literature review of Peinemann and Sauerland
[14] the risk of bias within the considered trials was ex-
amined using the predefined criteria shown in Table 2.
All five criteria had to be met for the potential for bias
to be described as low. The DiaFu- study is designed
with the aim of avoiding all potential bias.
Ethical conduct of the study
This study is conducted in accordance with the Inter-
national Conference on Harmonization (ICH) Harmonized
Tripartite Guidelines for Good Clinical Practice 1996, the
European Union (EU) Directive 95/46/EC on the protec-
tion of individuals with regard to the processing of per-
sonal data and on the free movement of such data as
transposed into national law, the EU Medical Device Di-
rective 93/42/EC as amended by Directive 2007/47/EC as
amended into national law, the International Organization
for Standardization (ISO) 14155 related to AE definitions
and in the spirit of the Declaration of Helsinki concerning
medical research in humans (latest edition).
Publication of study results
Both positive and negative results of the trial will be dis-
closed. The results of the trial will be submitted for publi-
cation to peer-reviewed scientific journals and presented
at international scientific congresses. The Principal Inves-
tigator and the Steering Committee are responsible for the
primary and secondary publications and/or presentations
arising from the study. All publications will maintain data
protection of participant data as well as data of the partici-
pating clinical investigators. Results will be reported ac-
cording to CONSORT recommendations [20].Trial status
Recruiting since December 2011.
Stop of recruitment estimated for 10/2014.
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